[go: up one dir, main page]

WO2008153135A1 - ナフタレン誘導体 - Google Patents

ナフタレン誘導体 Download PDF

Info

Publication number
WO2008153135A1
WO2008153135A1 PCT/JP2008/060865 JP2008060865W WO2008153135A1 WO 2008153135 A1 WO2008153135 A1 WO 2008153135A1 JP 2008060865 W JP2008060865 W JP 2008060865W WO 2008153135 A1 WO2008153135 A1 WO 2008153135A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen atom
optionally substituted
independently represent
different
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/060865
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Nakahira
Hitoshi Hochigai
Yohei Ikuma
Atsushi Suwa
Junya Ikeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of WO2008153135A1 publication Critical patent/WO2008153135A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　本発明は、レニン阻害剤として有用な式（Ｉ）の化合物、またはその薬学上許容される塩を提供する。 ［式中、Ｒ１ａは、置換されてもよいＣ１－６アルコキシ基等であり；Ｒ１ｂおよびＲ１ｅは、各々独立して、同一または異なって、水素原子、ハロゲン原子等であり；Ｒ１ｃおよびＲ１ｄは、各々独立して、同一または異なって、水素原子、ハロゲン原子等であり；Ｒ１ｆおよびＲ１ｇは、各々独立して、同一または異なって、水素原子、ハロゲン原子等であり；Ｒ２は置換されてもよいＣ１－６アルキル基等であり；Ｒ３ａ、Ｒ３ｂ、Ｒ３ｃおよびＲ３ｄは、各々独立して、同一または異なって基：－Ａ－Ｂ（ここにおいて、Ａは、単結合、－（ＣＨ２）ｓＯ－等であり、Ｂは、水素原子、置換されてもよいＣ１－６アルキル基等であり；Ｒ４は、水素原子、置換されてもよいＣ１－６アルキル基等であり；ｓは、０等であり；ｎは１等である。］
PCT/JP2008/060865 2007-06-14 2008-06-13 ナフタレン誘導体 Ceased WO2008153135A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007158075A JP2010189275A (ja) 2007-06-14 2007-06-14 ナフタレン誘導体
JP2007-158075 2007-06-14

Publications (1)

Publication Number Publication Date
WO2008153135A1 true WO2008153135A1 (ja) 2008-12-18

Family

ID=40129738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060865 Ceased WO2008153135A1 (ja) 2007-06-14 2008-06-13 ナフタレン誘導体

Country Status (2)

Country Link
JP (1) JP2010189275A (ja)
WO (1) WO2008153135A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
US8466282B2 (en) 2008-06-19 2013-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111003A1 (en) * 2003-06-17 2004-12-23 Pfizer Limited Amide derivatives as selective serotonin re-uptake inhibitors
WO2006066896A2 (en) * 2004-12-23 2006-06-29 Novartis Ag Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
JP2006522793A (ja) * 2003-04-10 2006-10-05 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 高血圧治療のためのレニン阻害剤としてのピペリジン誘導体
JP2006527758A (ja) * 2003-06-17 2006-12-07 ファイザー インコーポレイテッド セロトニン及びノルアドレナリン再取り込み阻害薬としてのｎ−ピロリジン−３−イル−アミド誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522793A (ja) * 2003-04-10 2006-10-05 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 高血圧治療のためのレニン阻害剤としてのピペリジン誘導体
WO2004111003A1 (en) * 2003-06-17 2004-12-23 Pfizer Limited Amide derivatives as selective serotonin re-uptake inhibitors
JP2006527758A (ja) * 2003-06-17 2006-12-07 ファイザー インコーポレイテッド セロトニン及びノルアドレナリン再取り込み阻害薬としてのｎ−ピロリジン−３−イル−アミド誘導体
WO2006066896A2 (en) * 2004-12-23 2006-06-29 Novartis Ag Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
US8466282B2 (en) 2008-06-19 2013-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8664380B2 (en) 2008-06-19 2014-03-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9045436B2 (en) 2008-06-19 2015-06-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9221836B2 (en) 2008-06-19 2015-12-29 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
US8658639B2 (en) 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative

Also Published As

Publication number Publication date
JP2010189275A (ja) 2010-09-02

Similar Documents

Publication Publication Date Title
WO2008136457A1 (ja) 含窒素芳香族誘導体
WO2009078481A1 (ja) 二環性へテロ環誘導体
WO2009054479A1 (ja) スピロ環化合物及びその医薬用途
WO2009048101A1 (ja) アミド化合物
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2008093737A1 (ja) アミド誘導体
WO2010066629A3 (en) Novel azaindoles
WO2008096829A1 (ja) ３環系化合物
WO2008096820A1 (ja) ビフェニル誘導体
WO2008146914A1 (ja) 複素環化合物
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
WO2007103508A3 (en) Ligands for nematode nuclear receptors and uses thereof
WO2009063990A1 (ja) ベンズアゼピノン化合物
WO2009005002A1 (ja) キノロン誘導体
MX2010001566A (es) Derivado de aminopirazolamida.
WO2009014217A1 (ja) 二環性ピロール誘導体
WO2008136385A1 (ja) アミド化合物およびその用途
SI2132204T1 (sl) Kristalinične oblike 8-azabiciklo(3.2.1) oktanske spojine
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2009063991A1 (ja) ピリドオキサゼピン誘導体およびその用途
WO2008153135A1 (ja) ナフタレン誘導体
WO2009072649A1 (ja) ４－アリールフェニル誘導体
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors
EP2239254A4 (en) BENZYLPIPERIZINVERBINDUNG
WO2007119004A3 (fr) Methode de diagnostic in vitro ou ex vivo de desordres psychiatriques et/ou de dysbioses intestinales

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765575

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08765575

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP